Insight Molecular Diagnostics Inc. Common Stock IMDX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$47.84M+17.8% | -$50.22M+17.2% | -$60.78M-40.9% | -$63.42M-75.5% | -$58.21M-45.7% | ||
| $2.34M+41.9% | $2.19M+48.4% | $2.17M+75.1% | $1.9M+43.7% | $1.65M+13.2% | ||
| $2.36M+30.6% | $2.22M+26.6% | $2M+14.9% | $1.93M+1.6% | $1.81M-22.9% | ||
| —— | —— | $49K— | $427K— | $3.38M— | ||
| —— | —— | —— | $693K— | $459K— | ||
| $1.51M+32.8% | $2.65M+174% | -$205K+31.9% | -$733K+22.8% | $1.14M+183% | ||
| —— | —— | —— | $569K+467% | $465K+400% | ||
| $14.59M-65.2% | $14.6M-65.2% | $41.84M— | $41.86M— | $41.89M— | ||
| -$195K+13.3% | -$142K+51.2% | -$290K-55.1% | -$233K— | -$225K— | ||
| —— | —— | -$6.64M— | -$2.87M— | -$6.71M— | ||
| -$23.98M-5.7% | -$22.18M-7.2% | -$21.99M-11.3% | -$23.02M-27.9% | -$22.7M-20.4% | ||
| $3.49M+337% | $3.19M+517% | $1.92M+239% | $957K— | $799K— | ||
| -$3.49M-339% | -$3.19M-522% | -$1.92M— | -$953K— | -$795K— | ||
| —— | —— | —— | —— | $55.16M+431% | ||
| —— | $72K— | $54K— | $36K— | $18K— | ||
| —— | $2K— | $1.5K— | $1K— | $500— | ||
| —— | —— | —— | —— | $49.24M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $86K+30.3% | $91K+117% | $94K+401% | $87K+2,386% | $66K+1,157% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0-100% | $7K-92.0% | $29K-67.0% | $51K-42.0% | $73K-17.0% | ||
| —— | —— | -$6.64M— | -$2.87M— | -$6.71M— | ||
| $182K— | $164K— | $176K— | $152K— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$195K+13.3% | -$142K+51.2% | -$290K-55.1% | -$233K— | -$225K— | ||
| —— | —— | —— | $569K+467% | $465K+400% | ||
| —— | —— | —— | —— | $1.86M+481% | ||
| $555K— | $510K— | $414K— | $380K— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$195K+13.3% | -$142K+51.2% | -$290K-55.1% | -$233K— | -$225K— | ||
| $1.05M-7.3% | $1.14M-36.6% | $373K— | $813K— | $1.13M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $2K— | $1.5K— | $1K— | $500— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$27.48M-16.9% | -$25.37M-19.6% | -$23.91M-17.6% | -$23.98M— | -$23.5M— | ||
| -$27.48M-16.9% | -$25.37M-19.6% | -$23.91M-17.6% | -$23.98M— | -$23.5M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.
- What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?
- After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.
- Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
